The use of electronic health records (EHRs) saved more than 3% in ambulatory health costs but did not reduce overall inpatient costs, according to a new study.
The use of electronic health records (EHRs) saved more than 3% in ambulatory health costs but did not reduce overall inpatient costs, according to a new study.
Published in the July 16, 2013, issue of Annals of Internal Medicine, the study was led by Julia Adler-Milstein with the University of Michigan in Ann Arbor, Mich.
Adler-Milstein and colleagues based the findings on 806 ambulatory clinicians across 3 Massachusetts communities that adopted subsidized EHRs. The study group was comprised of 47,979 intervention patients and 130,603 control patients. The researchers reviewed monthly standardized healthcare costs from commercial claims data from January, 2005, to June, 2009, including total cost, inpatient cost, and ambulatory cost-including pharmacy expenses.
They found that ambulatory EHR adoption did not impact total cost, but the results favored savings (95% CI, $21.95 projected savings per member per month (PMPM) to $1.53 PMPM in higher costs). However, EHRs slowed ambulatory cost growth (-0.35 percentage point) and projected ambulatory savings were $4.69 PMPM.
“Using commercially available EHRs in community practices seems to modestly slow ambulatory cost growth,” Adler-Milstein wrote. “Broader changes in the organization and payment of care may prompt clinicians to use EHRs in ways that result in more substantial savings,” she added.
However, a limitation of the study was that intervention communities were not randomly selected and received implementation support, suggesting that results may represent a best-case scenario, according to the researchers.å
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More